Eric S Daar

Generalizing evidence from randomized trials using inverse probability of sampling weights

Michael G Hudgens, Stephen R Cole, Michael J Mugavero, 2018, Journal of the Royal Statistical Society. Series A,.

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.

Simon D W Frost, D. Richman, S. Little, 2003, The Journal of infectious diseases.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Matthew C Strain, Diane V Havlir, D. Richman, 2005, The Journal of infectious diseases.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Antiretroviral-drug resistance among patients recently infected with HIV.

Elizabeth Connick, Richard A Koup, Lei Wang, 2002, The New England journal of medicine.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Marylyn D Ritchie, Gene D Morse, Benjamin J. Grady, 2012, Pharmacogenetics and genomics.

Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance

Susanne May, Christopher H Woelk, J. Margolick, 2008, AIDS.